Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FUSN

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Key Stats

Today's Range
$21.55
$21.55
50-Day Range
$21.38
$21.55
52-Week Range
$2.31
$21.60
Volume
N/A
Average Volume
1.69 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.25
Consensus Rating
Hold

Company Overview

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FUSN Stock News Headlines

Fusion Pharma (FUSN) Earnings Dates & Reports
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

FUSN Stock Analysis - Frequently Asked Questions

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.13. The company earned $0.33 million during the quarter. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 48.74%.

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FUSN
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.25
High Stock Price Target
$24.00
Low Stock Price Target
$15.00
Potential Upside/Downside
-6.0%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
14 Analysts

Profitability

Net Income
$-94,900,000.00
Net Margins
-4,136.55%
Pretax Margin
-5,084.07%

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$3.07 per share

Miscellaneous

Free Float
78,468,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
-0.69
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:FUSN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners